Pritesh Kumar

CEO

Dr. Pritesh Kumar earned his Ph.D. in Pharmacology and Toxicology, with a focus in cannabinoid (cannabis) pharmacology, from the University of Louisville. Dr. Kumar is a cannabinoid research scientist, pharmacologist, laboratory manager and consultant trained in ensuring Quality Assurance/Quality Control (QA/QC), current Good Manufacturing Practices (cGMP), current Good Production Practices (GPP), and current Good Laboratory Practices (cGLP) of pharmaceutical products and Active Pharmaceutical Ingredients (APIs). Currently, Dr. Kumar is the CEO of PhytoSciences and leads a team of 40+ global scientists / physicians with a primary focus of developing safe, consistent, and pure medicinal cannabinoid-based therapeutics. Overall, Dr. Kumar’s experience and expertise lead the product development operations at PhytoSciences and their team consults in the areas of R & D, manufacturing, bioprocessing, clinical trial solutions, and laboratory development pertaining to cannabinoid-based therapeutics.

Dr. Kumar has provided consulting services to several U.S. state government officials as well as international governments and policy officials on effective medical cannabis policies and regularly advises on laboratory facility design / optimization, cannabis testing equipment, analytical methodology for cannabinoid analysis and separation, pharmacology of cannabis-based therapeutics and maintaining a QA system to ensure compliance, including preparation of legislative documents to regulate a QA system with regard to cannabis manufacturing and processing.

Previously, at the University of Louisville, Dr. Kumar conducted pharmacological testing of FDA- approved drugs as potential ligands for the cannabinoid receptor 2 (CB2) and investigated the pharmacology of cannabidiol (CBD). Currently, Dr. Kumar is the primary investigator of the largest harm-reduction cohort study across Canada investigating medical cannabis as a potential substitute for opioids for chronic pain patients.

He has received numerous honors and awards including Best Oral Presentation from the International Cannabinoid Research Society (ICRS) Conference in Vancouver and fellowships from Drug Discovery and Target in Boston and Integrated Programs in Biomedical Sciences (IPIBS) as well as travel awards from the National Institute on Drug Abuse and University of Louisville School of Medicine for his presentations in the U.S., Canada, Italy, and Germany. Dr. Kumar’s research pertains to the pharmacological testing of FDA approved drugs as potential ligands for CB2 and investigates the pharmacology of several cannabinoids for CB2.

Dr. Kumar has been published in numerous scientific journals including the European Journal of Pharmacology, Pharmacology and Physiology, Journal of Medicinal Chemistry, Investigative Ophthalmology & Visual Science and Biochemical and Biophysical Research Communications, authored a book chapter on polymorphisms in the cannabinoid receptor 2 and related impacts to certain pathologies and has presented at several international symposiums.